Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Assets Average (2016 - 2025)

Enanta Pharmaceuticals filings provide 13 years of Assets Average readings, the most recent being $305.1 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 15.86% to $305.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $305.1 million, a 15.86% decrease, with the full-year FY2025 number at $328.7 million, down 21.64% from a year prior.
  • Assets Average hit $305.1 million in Q4 2025 for Enanta Pharmaceuticals, up from $290.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $478.7 million in Q3 2023 to a low of $290.9 million in Q3 2025.
  • Median Assets Average over the past 5 years was $401.1 million (2022), compared with a mean of $393.6 million.
  • Biggest five-year swings in Assets Average: increased 25.88% in 2023 and later dropped 24.98% in 2025.
  • Enanta Pharmaceuticals' Assets Average stood at $439.7 million in 2021, then dropped by 17.79% to $361.5 million in 2022, then increased by 23.21% to $445.4 million in 2023, then fell by 18.58% to $362.6 million in 2024, then decreased by 15.86% to $305.1 million in 2025.
  • The last three reported values for Assets Average were $305.1 million (Q4 2025), $290.9 million (Q3 2025), and $312.0 million (Q2 2025) per Business Quant data.